About BiomX
BiomX is a company based in Ness Ziona (Israel) founded in 2015. It operates as a HealthTech. BiomX has raised $56 million across 7 funding rounds from investors including Chong Kun Dang Pharmaceutical, Handok and Orbimed. The company has 57 employees as of December 31, 2024. BiomX has completed 2 acquisitions, including Adaptive Phage Therapeutics and RondinX. BiomX offers products and services including BX004, BX211, BX005, and XMarker. BiomX operates in a competitive market with competitors including Adaptive Phage Therapeutics, Armata Pharmaceuticals, Aurealis Therapeutics, NovaLead Pharma and Pherecydes Pharma, among others.
- Headquarter Ness Ziona, Israel
- Employees 57 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biomx Inc.
-
Annual Revenue
Not available
-
Net Profit
-$17.73 M (USD)32.26as on Dec 31, 2024
-
EBITDA
-$37.22 M (USD)-38.82as on Dec 31, 2024
-
Total Equity Funding
$56 M (USD)
in 7 rounds
-
Latest Funding Round
$3.3 M (USD), Post-IPO
Jan 13, 2026
-
Investors
Chong Kun Dang Pharmaceutical
& 17 more
-
Employee Count
57
as on Dec 31, 2024
-
Investments & Acquisitions
Adaptive Phage Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BiomX
BiomX is a publicly listed company on the AMEX with ticker symbol PHGE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BiomX
BiomX offers a comprehensive portfolio of products and services, including BX004, BX211, BX005, and XMarker.
Phage therapy targeting bacteria in cystic fibrosis treatment.
Phage therapy developed for diabetic foot infections.
Phage therapy candidate for atopic dermatitis treatment.
Platform used for microbiome-based biomarker discovery.
People of BiomX
Unlock access to complete
Unlock access to complete
Funding Insights of BiomX
BiomX has successfully raised a total of $56M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.3 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BiomX
BiomX has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Chong Kun Dang Pharmaceutical, Handok and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Investments are made in antimicrobial resistance treatment development.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for BiomX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BiomX
BiomX has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adaptive Phage Therapeutics and RondinX.
Investment portfolio details for BiomX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Locked | Locked | 2016 | Locked | |
|
Microbiome drug discovery platform for therapeutics and diagnostics is offered.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for BiomX
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - BiomX
Detailed financials for BiomX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomx Comparisons
Peer comparison for BiomX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BiomX
BiomX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Phage Therapeutics, Armata Pharmaceuticals, Aurealis Therapeutics, NovaLead Pharma and Pherecydes Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Phage therapeutics are developed to target antibiotic-resistant bacteria.
|
|
| Locked | Locked | Locked |
Provider of cell & gene therapy platforms for chronic wounds, cancer, and inflammatory diseases
|
|
| Locked | Locked | Locked |
Drug repurposing and discovery are enabled by a proprietary platform.
|
|
| Locked | Locked | Locked |
French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections
|
Detailed competitors of BiomX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomx
Complete news archive for BiomX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BiomX
BiomX was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BiomX is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
BiomX is a funded company, having raised a total of $56M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at BiomX is 57.
BiomX is engaged in the development of natural and engineered phage cocktails as well as personalized treatments aimed at eradicating harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. Proprietary bacterial targets are discovered and validated by BiomX, with customized phage compositions being developed against these targets. The company also utilizes the XMarker platform for microbiome-based biomarker discovery, particularly for inflammatory bowel disease. Collaborations with industry leaders like Janssen Pharmaceuticals and Boehringer Ingelheim are maintained to advance therapeutic solutions and biomarker identification.
BiomX's top competitors include Adaptive Phage Therapeutics, Armata Pharmaceuticals and Aurealis Therapeutics.
BiomX offers BX004, BX211, BX005, and XMarker.
Yes, BiomX is publicly traded on AMEX under the ticker symbol PHGE.
BiomX has made 2 acquisitions, including Adaptive Phage Therapeutics, and RondinX.
BiomX has 18 investors. Key investors include Chong Kun Dang Pharmaceutical, Handok, Orbimed, Cystic Fibrosis Foundation, and KB Investment.
The ticker symbol of BiomX is PHGE on AMEX.